The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma
暂无分享,去创建一个
S. H. van der Burg | C. Taube | P. Hiemstra | M. Fiocco | T. van Hall | S. van Riet | A. van Schadewijk | Mehrdad Talebian Yazdi
[1] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[2] David C. Smith,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[4] S. Natsugoe,et al. Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer. , 2015, Anticancer research.
[5] W. Liang,et al. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. , 2015, Journal of thoracic disease.
[6] H. An,et al. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. , 2015, Journal of thoracic disease.
[7] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[8] R. Herbst,et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.
[9] P. Validire,et al. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.
[10] H. Ditzel,et al. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[11] Nivolumab approved for lung cancer. , 2015, Cancer discovery.
[12] S. H. van der Burg,et al. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapy , 2014, International journal of cancer.
[13] Douglas B. Johnson,et al. Immune Checkpoint Inhibitors in NSCLC , 2014, Current Treatment Options in Oncology.
[14] Grazyna Kochan,et al. Role of non-classical MHC class I molecules in cancer immunosuppression , 2013, Oncoimmunology.
[15] F. Tanaka,et al. Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. , 2013, The Journal of surgical research.
[16] H. Uramoto,et al. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer. , 2013, Anticancer research.
[17] You-jian He,et al. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer , 2013, Medical Oncology.
[18] F. Tanaka,et al. Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients , 2013, International Journal of Clinical Oncology.
[19] E. Jordanova,et al. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival , 2012, Journal of Translational Medicine.
[20] C. Volteau,et al. HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression , 2012, International journal of cancer.
[21] A. Jemal,et al. Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[22] J. Coebergh,et al. Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Wenfu Zhou,et al. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. , 2011, Lung cancer.
[24] S. H. van der Burg,et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.
[25] Rafael Sirera,et al. The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] H. Putter,et al. HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.
[27] T. Ottenhoff,et al. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. , 2010, Microbes and infection.
[28] E. Miyaoka,et al. Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] M. Bianchini,et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells , 2009, Innate immunity.
[30] L. Tanoue,et al. New TNM classification for non-small-cell lung cancer , 2009, Expert review of anticancer therapy.
[31] E. Carosella,et al. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. , 2008, Human immunology.
[32] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[33] T. Dønnem,et al. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[34] C. Melief,et al. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.
[35] M. Nishimura,et al. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. , 2008, Cancer immunity.
[36] Hong Yang,et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. , 2007, Lung cancer.
[37] M. Nishimura,et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer , 2007, Cancer science.
[38] A. Moreau,et al. Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.
[39] T. Oshikiri,et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.
[40] S. Ferrone,et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? , 2006, Cancer Immunology, Immunotherapy.
[41] B. Bellosillo,et al. The CD94/NKG2C killer lectin‐like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells , 2005, European journal of immunology.
[42] Anthony J Alberg,et al. Epidemiology of lung cancer: looking to the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Bell,et al. Functional characterization of HLA‐F and binding of HLA‐F tetramers to ILT2 and ILT4 receptors , 2000, European journal of immunology.
[44] P. A. Peterson,et al. Cell surface expression of HLA‐E: interaction with human β2‐microglobulin and allelic differences , 1999, European journal of immunology.
[45] B. Nielsen,et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. , 1998, European journal of cancer.
[46] A. Harris,et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.